Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-01

Clinical Trial Update: Tofacitinib for Inflammatory Eye Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tofacitinib for inflammatory eye diseases (uveitis and scleritis) with results posted in 2021; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tofacitinib (tofacitinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Uveitis, Scleritis | Phase 2 | Status: UNKNOWN | Results posted: 2021-02-01